The purpose of this legislation, known as the Expedited Access to Biosimilars Act, is to streamline the process for licensing biological products as biosimilars. Biosimilars are medications that are highly similar to an already approved biological product, and the aim of this act is to clarify the requirements for their approval, making it easier and faster for these products to enter the market. Key provisions of the act include changes to the requirements for clinical studies needed for biosimilar licensure.